- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
Population: Adults (18-64 years)
- Adults (18-64 years)
- General population
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Blood sample
- Adults (18-64 years)
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Blood sample
- Adults (18-64 years)
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Community
- SARS-CoV-2
- Nasopharyngeal swab
- Non pharmacological intervention
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Infectious diseases unit
- SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Tixagevimab/Cilgavimab